Introduction
Protein kinase C (PKC) proteins are serine/threonine protein kinases that exert an important function in signal transduction pathways mediating cell growth and survival of normal and tumor cells (Gutcher et al. 2003) . PKC is constitutively activated in malignant glioma cells (da Rocha et al. 2002) . Further key properties of malignant gliomas include (i) reduced proliferation in response to staurosporine-or CGP41251-induced inhibition of PKC (Baltuch & Yong 1996; Yamasaki et al. 2003) and (ii) increased apoptosis mediated by staurosporine (Couldwell et al. 1994) and by downregulation of PKC-ε (Okhrimenko et al. 2005) . Altogether, these data suggest a survival function for PKC in glioma cells.
ENZA (LY317615.HCl) is a novel, orally available small-molecule PKC inhibitor with
increased selectivity for PKC-β isoforms. It elicits anti-tumoral activity and is currently under clinical investigation (Carducci et al. 2006) . One proposed mechanism underlying its antitumor effects is inhibition of angiogenesis. PKC is required for tumor-induced angiogenesis, and inhibition of PKC by the PKC-β-selective inhibitor LY333531 inhibited the vascular endothelial growth factor (VEGF)-induced growth of hepatocellular carcinoma (Yoshiji et al. 1999) . Similarly, ENZA exerted antiangiogenic properties in a rat corneal micropocket (Teicher et al. 2002) and in tumor xenografts (Keyes et al. 2004 ).
Furthermore, ENZA induced apoptosis in HCT116 colon carcinoma cells and in multiple myeloma cells as well as U87MG glioma cells and inhibited tumor growth in a xenograft model (Graff et al. 2005; Rizvi et al. 2006) . ENZA-induced apoptosis was associated with suppression of the Akt signaling pathway. Additionally, glycogen synthase kinase 3β (GSK-3β) was dephosphorylated during treatment with ENZA in vitro and in an U87MG xenograft model (Graf et al. 2005) . Hence, GSK-3β dephosphorylation has been suggested to be a pharmacodynamic marker of ENZA activity. In addition, treatment of T cell lymphoma cell lines with ENZA induced apoptosis associated with dephosphorylation of protein kinase B (PKB)/Akt (Querfeld et al. 2006) . Recently, we reported synergistic effects of ENZA and irradiation in both the induction of apoptosis in vitro and the treatment of orthotopic LNT-229 gliomas in nude mice (Tabatabai et al. 2007) . Here, we investigated the mechanisms underlying ENZA-induced glioma cell apoptosis and the role of ENZA-dependent dephosphorylation of Akt and GSK-3β in that process.
Materials and Methods
Materials. All chemicals were purchased from Sigma (Deisenhofen, Germany) unless otherwise indicated. LY294002, an inhibitor of phosphatidylinositol 3 kinase (PI3K), was obtained from Calbiochem (Schwalbach, Germany). Wortmannin, another inhibitor of PI3K, the caspase inhibitor zVAD-fmk and Ac-DEVD-amc were from Bachem (Weil am Rhein, Germany). ENZA was provided by Eli Lilly (Indianapolis, IN). It was solubilized in DMSO at 10 mM and stored at -20°C. As a control, DMSO was used in the experiments. Apo2L.0 was provided by A. Ashkenazi (Ashkenazi et al. 1999) .
Cell culture. The glioma cell lines have been described previously. Glioma cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum (FCS), 100 IU/ml penicillin and 100 ng/ml streptomycin (Cambrex, Verviers, Belgium). LNT-229 neo control transfected cells and LNT-229 BCL-X L expressing as well as T98G puro control transfected cells and T98G cytokine response modifier-A (crm-A) cells were generated as described (Wagenknecht et al. 1998; Steinbach et al. 2003) .
Primary tumor spheres. Tumor samples were obtained from adult patients diagnosed with glioblastoma after informed consent. The technique to obtain tumor and neurosphere cultures was modified from Svendsen et al. (1998) . Briefly, tissue was washed, minced, digested with trypsin, dissociated, and passed through a 100 µm cell strainer. Cells were seeded in neural stem cell medium (NSCM) containing DMEM:F12 growth medium enriched with B27 supplement, basic fibroblast growth factor (bFGF) (20 ng/ml), epidermal growth factor (EGF) (20 ng/ml) and leukemia inhibitory factor (LIF) (20 ng/ml) (Hemmati et al. 2003) . To obtain adherent, differentiated cells, tumor cells were cultured in serum-containing medium (10% FCS) in parallel.
Crystal violet staining. For crystal violet staining, glioma cell lines were seeded at 20,000 cells per well in 96-well plates in DMEM/10% FCS. After 24 h, medium was removed, cells were treated in serum-free medium (SFM) as indicated, and viable cells were stained with crystal violet.
Trypan blue staining. Glioma cells were seeded at 50,000 cells per well in 24-well plates in DMEM/10% FCS. After 24 h, medium was removed, and cells were treated as described in SFM for 48 h. Thereafter, cells and supernatants were collected, trypan blue solution was added, and unstained and trypan blue-stained cells were counted.
Self-renewal capacity. Self-renewal was measured after primary sphere formation was noted. Spheres were kept in NSCM, and their differentiated counterparts were kept in SFM with 10% FCS. In case spheres did not have a counterpart that grew in serum-containing medium, self-renewal of the spheres was determined in NSCM compared to the number of colonies growing under differentiation-inducing conditions with 10% FCS. After dissociation, cells were plated in 96-well microwell plates in 0.2 ml volumes of NSCM or medium with 10% FCS at 75 cells/well. Twelve wells were plated per experiment. Cultures were supplemented with 0.025 ml of NSCM or medium with 10% FCS every 3 days until day 7. At day 7, the number of colonies per well was counted after fluorescence labelling of the cells with MitoTracker Red (Invitrogen, Karlsruhe, Germany). Sensitivity to ENZA at 5 µm was analyzed by plating the cells in ENZA-containing medium.
Proliferation. Neurosphere cells at 10.000 cells/well and their differentiated counterparts were dissociated and plated in quadruplicates in 96-well plates in 200 µl volumes of NSCM and SFM supplemented with 10% FCS. To assess radio-or chemosensitivity, cells were treated as described above. After 24 h, cells were pulsed for another 24 h with [methyl- 3 H]thymidine (0.5 µCi), harvested (Tomtec, Hamden, CT), and incorporated radioactivity was determined in a liquid scintillation counter (Wallac, Turku, Finland) (Uhl et al. 2004) .
Immunoblot analysis. Cells were treated as described in SFM. Thereafter, cells were washed with ice-cold phosphate-buffered saline (PBS) and harvested into PBS with phenylmethylsulfonylfluoride (PMSF). The cells were centrifuged, lysed in lysis buffer P (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 100 µg/ml PMSF) containing 10 µg/ml leupeptin, 2 µg/ml aprotinin and phosphatase inhibitor cocktails 1 and 2, and subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). containing digitonin (40 µg/ml) at 4°C. The buffer was removed and centrifuged at 13,000 rpm. The supernatant was transferred to another cup, and 600 µl of trichloracetic acid 10% was added. After incubation for 30 min at -20°C and centrifugation at 13,000 rpm, the supernatant was removed, and the cups were dried.
Thereafter, 50 µl Laemmli buffer, diluted in lysis buffer P, and 1 µl mercaptoethanol was added. After denaturating for 5 min at 95°C, 25 µl were used for cytochrome c immunoblot analysis.
Cell cycle analysis. The cells were treated as described. Detached cells were collected, adherent cells were trypsinized and added to the detached cells, and washed with PBS. Thereafter, cells were incubated for 30 min with ethanol 50%, washed with PBS, and incubated with propidium iodide (50 µg/ml) for 20 min, and analyzed in a DAKO CyAn flow cytometer (Glostrup, Denmark).
Methyl-guanly-methyl-transferase (MGMT) promoter analysis.
A tumor cell content of at least 80% was histologically determined. From each sample and the reference samples 200 to 500 ng of genomic DNA were treated with sodium bisulfite using the Qiagen EpiTect kit (Qiagen, Hilden, Germany) with the provided FFPE tissue protocol. The primer sequences used to detect methylated MGMT promoter sequences were 5′-tttcgacgttcgtaggttttcgc-3′ and 5′-gcactcttccgaaaacgaaacg-3′. This primer combination amplifies an 81-base pair (bp) fragment from methylated DNA.
The primer sequences used to detect unmethylated MGMT promoter sequences were 5′-aactccacactcttccaaaaacaaaaca-3′ and 5′-tttgtgttttgatgtttgtaggtttttgt-3′. This primer combination amplifies a 93-bp fragment from unmethylated DNA (Esteller et al. 2000) . The PCR products were separated on 2.5% agarose gels. As a positive control for methylation, we used genomic DNA from the glioma cell line U87 with known MGMT hypermethylation. CpGenome universal unmethylated DNA Vial A (Chemicon International, Temecula, CA) served as a negative control for methylation.
In addition, a control reaction without any template DNA was performed for both PCR experiments.
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Statistical analysis. Statistical significance was assessed by unpaired t-test (Excel,
Microsoft, Seattle, WA). Synergy was determined by the fractional product method. A difference of more than 10% between observed and predicted effect was considered to signify synergistic activity.
Results

ENZA induces apoptosis in glioma cells. ENZA at 5 µM reduced the survival of T98G
cells whereas ENZA inhibited proliferation in A172 cells but did not lead to cell death in a time-dependent manner as observed in T98G cells (Fig. 1a) . In primary glioma cells, designated as glioblastoma-initiating cells and kept in NSCM, T 269 and T 323, proliferation and self-renewal capacity were reduced with clinically relevant doses of ENZA. Interestingly, no differential sensitivity was observed between T 323 cells either kept in NSCM or in differentiating conditions (Fig. 1b) . To further characterize the type of cell death, we analyzed the cell cycle distribution of ENZA-treated cells by flow cytometry. In T98G cells, treatment with ENZA resulted in an increase of the sub-G1 fraction, indicating induction of apoptosis. Furthermore, we observed a reduction of the G1 peak in these cells. There were no distinct alterations in the cell cycle distribution in ENZA-treated A172 cells, suggesting a cell cycle-independent growth inhibition (Fig. 1c) . With the objective of more closely modeling the clinical situation, we also analyzed freshly prepared glioma cells that in low quantities give rise to glioma in nude animals and form spheroids (data not shown) and are therefore designated glioma-initiating cells. Both cells were also positive for CD133, a marker linked to glioma-initiating cells in some studies, and showed a methylated promoter of the MGMT gene in T 323 and an unmethylated MGMT promoter in T 269 cells.
However, there were no alterations in the cell cycle distribution in ENZA-treated T 269 and T 323 cells, indicating that these cells did not undergo apoptosis in response to ENZA as analyzed by flow cytometry (data not shown).
ENZA induces activation of caspases and release of cytochrome c. We next investigated the levels of proteins important for the execution of apoptosis. In T98G cells, ENZA induced the cleavage of caspases 3, 8 and 9 (Fig. 2a) . No caspase cleavage was detectable in A172 cells. Similarly, increased Ac-DEVD-amc cleavage was detected in ENZA-treated T98G but not in A172 cells (Fig. 2b) . As the two mitochondrial proteins BCL-2 and BCL-X L are known to be important modulators of apoptosis, we also examined the levels of these proteins. Neither BCL-2 nor BCL-X L levels were consistently altered in response to ENZA (Fig. 2a) . We also examined possible changes in Bid levels. Cleavage of Bid by caspase 8 has been shown to connect the death ligand-induced apoptotic signal to the mitochondria (Li et al. 1998 ).
However, we did not detect cleavage of Bid in ENZA-treated cells (Fig. 2a) .
Additionally, ENZA induced a strong release of cytochrome c into the cytosol in T98G
cells, but not in A172 cells (Fig. 2c , not shown). These results suggest that caspases are activated via mitochondrial cytochrome c release during ENZA-induced apoptosis.
Caspases are critical for induction of cell death by ENZA. To figure out whether the observed activation of caspases is critical for ENZA-induced cell death, we analyzed cell death in T98G cells treated with ENZA in the presence of the caspase inhibitor zVAD-fmk. zVAD-fmk inhibited cell death as well as ENZA-induced activation of caspases in T98G cells (Fig. 3a) . Compared with untreated cells, the reduced density of cells co-treated with ENZA and zVAD-fmk indicates that ENZA induced growth inhibition in the presence of zVAD-fmk. Furthermore, the formation of a sub-G1 peak induced by ENZA was largely prevented by zVAD-fmk (Fig. 3b) . To investigate whether the activation of caspase 8 is fundamental to the induction of cell death, T98G cells expressing the viral caspase 1/8 inhibitor crm-A were exposed to ENZA.
Crm-A inhibited ENZA-induced cell death only insignificantly, suggesting that caspase 8 does not relevantly contribute to ENZA-induced cell death. Control experiments demonstrated that CD95 ligand (CD95L)-induced apoptosis was strongly prevented by crm-A, and zVAD-fmk also inhibited cell death induced by ENZA and CD95L ligand (Fig. 3c) . release of cytochrome C (data not shown) and cleavage of Ac-DEVD-amc (Fig. 4a-c) .
Modulation of ENZA-induced apoptosis
Compared with control transfectants, T98G cells over-expressing BCL-X L were also protected against ENZA-induced cell death (data not shown). by ENZA at 1 h and 2 h whereas in A172 cells, phosphorylation remained unchanged. Phosphorylation of ERK1/2 was induced in both cell lines in response to ENZA for 3 h to 24 h. As expected from the mechanism of action (Graff et al. 2005) and in line with our data observed with LNT-229 cells (Tabatabai et al. 2007) , ENZA resulted in a strong dephosphorylation of GSK-3β in both cell lines. Moreover, phosphorylation of mammalian target of rapamycin (mTOR) was reduced in T98G cells in response to treatment with ENZA at 6 h and 24 h. We next analyzed activation of p70 S6 kinase that is phosphorylated by protein 3-phosphoinositidedependent kinase 1 (PDK-1) and Akt (Shamji et al. 2003) , and of its substrate S6
Modulation
protein.
In ENZA-sensitive T98G cells, phosphorylation of p70 S6 kinase and S6
protein was reduced after 6 h and 24 h. In contrast, phosphorylation of p70 S6 kinase and S6 protein in A172 cells remained unaltered within 24 h (Fig. 5A ) and even after prolonged ENZA-treatment for 48 h (Fig. 5b) . We also examined phosphorylation of p70 S6 kinase and S6 protein in LNT-229 neo and LNT-229 BCL-X L cells and found that phosphorylation of both kinases was similarly reduced in both transfectands in response to treatment with ENZA. Furthermore, we also detected reduced phosphorylation of GSK-3β in LNT-229 neo and BCL-X L cells in response to ENZA (Fig. 5c ).
Role of Akt in ENZA-dependent induction of cell death. As dephosphorylation of Akt
has been suggested to be crucial for ENZA-induced cell death (Graff et al. 2005) , we aimed at investigating the role of PI3K signaling in ENZA-induced cell death. First, we examined whether inhibition of PI3K sensitized A172 cells towards ENZA. Efficient inhibition was obtained at 2 h of treatment with the PI3K inhibitor LY294002, as demonstrated by the loss of Akt Ser473 dephosphorylation (Fig. 6a, upper panel) . In contrast, treatment with ENZA alone had no influence on Akt phosphorylation, consistent with the results shown in Fig. 2a . However, combined treatment with ENZA and LY294002 resulted in a sustained dephosphorylation of Akt Ser473 at 24 h, whereas treatment with ENZA or LY294002 alone had not such an effect during that time interval (Fig. 6a, upper panel) . We next determined phosphorylation of GSK-3β in A172 cells in response to treatment with ENZA or LY294002: ENZA but not LY294002 inhibited the phosphorylation of GSK-3β. Further, we did not observe activation of caspase 3 cells by ENZA in A172, LY294002, or both at 2 or 24 h. In line with these results, LY294002 reduced growth of A172 cells but did not sensitize them towards ENZA-induced cell death (Fig. 6a, lower panel) . These experiments indicate that Akt signaling is not underlying the mechanism of resistance towards ENZA in (Fig. 6b) . Similarly, we did not observe protection from ENZA-induced cell death by expression of Akt in T98G cells (data not shown).
ENZA increases Apo2L.0-induced cell death.
We have recently shown that ENZA and radiotherapy act synergistically in inducing cell death (Tabatabai et al. 2007 ).
Moreover, caspase 8, an initiator caspase of death receptor-mediated apoptosis, was cleaved in response to ENZA-treatment in T98G cells (Fig. 2a) . Therefore, we speculated whether ENZA modulates cell death induced by the tumor necrosis factor 
Discussion
ENZA is a novel PKC-β inhibitor with antitumor activity that is currently under clinical investigation in several tumor entities including recurrent and newly diagnosed glioblastoma (Carducci et al. 2006) . Several mechanisms by which ENZA exerts its antitumor effects have been described: First, ENZA has been shown to have antiangiogenic properties associated with decreased VEGF levels (Keyes et al. 2004) . Supporting these observations, antiglioma activity of ENZA has been shown in a mouse xenograft model (Tabatabai et al. 2007) . In these experiments, it was further observed that treatment with ENZA resulted in synergistic activity with irradiation and reduced expression of VEGF in vitro and in vivo leading to reduced vessel density in glioma xenografts. Second, ENZA has direct cell death-inducing properties in tumor cells in vitro (Graff et al. 2005) . Still, the mechanisms of ENZA-dependent cell death induction have remained unclear. Recently, for gastric cancer cells, it has been shown that ENZA induces apoptosis through ribosomal S6 kinase (Rsk)-and Badmediated pathways, besides inhibiting the Akt signaling cascade (Lee et al. 2008 ).
In the work at hand, we observed that ENZA at clinically achieved concentrations (Rademaker-Lakhai et al. 2007; Robertson et al. 2007; Carducci et al. 2006 ) induced apoptosis in LNT-229 (Tabatabai et al. 2007 ) and T98G glioma cells, but not in A172 glioma cells (Fig. 1, 6 ), indicating that ENZA-induced cell death is not a general but rather a cell type-specific phenomenon. Therefore, we comparatively used T98G
(sensitive) and A172 (resistant) glioma cells in our experiments. However, primary glioma cells, designated as glioma-initiating cells show reduced proliferation and selfrenewal but no cell death in response to ENZA. This underlines the relevance of ENZA treatment and suggests an effect of ENZA not only on the tumor bulk but also on cells that are thought to maintain tumor growth (Gilbertson & Rich 2007) .
However, specific resistance mechanisms might be in place in the resistance to cell death in the glioma-initiating cell subgroup (Fig. 1b) . In a gene expression analysis of cases from the EORTC 26981/NCIC CE 3.0 study CD133, expression of epidermal growth factor receptor (EGFR) and MGMT promoter methylation status were independent prognostic factors, with MGMT conferring an additional predictive value for the response to chemotherapy (Murat et al. 2008) . However, in our analysis, MGMT promoter methylation done for both tumors (T 269 unmethylated and hence active and T323 methylated and hence inactive) in the clinical setting, as expected, does not explain the resistance to ENZA, which does not have alkylating properties.
In addition, CD133 expression in our hands does not discriminate between ENZAsensitive and -insensitive tumors (data not shown). A larger study of the EORTC on the EGFR inhibition demonstrated no predictive value of EGFR expression but also a merely prognostic value (van den Bent et al. 2007 ). Analysis of the signaling pathways underlying ENZA-induced cell death could help to understand the differential sensitivity and might lead to efficient combination treatments with ENZA.
ENZA-treatment of T98G and LNT-229 cells, but not of A172 cells, resulted in the activation of caspases 3 and 9. Furthermore, cleavage of caspase 8, an initiator caspase of death receptor-mediated apoptosis, was observed in T98G cells in response to ENZA (Fig. 2a) . However, expression of crm-A, a viral inhibitor of caspases 1 and 8, only weakly inhibited apoptosis, suggesting that activation of caspase 8 is not critical for ENZA-induced apoptosis (Fig. 3c) . In contrast, the pancaspase inhibitor zVAD-fmk strongly inhibited ENZA-induced activation of caspases and apoptosis (Fig. 3) . These results are in line with a report demonstrating that in cutanous T cell lymphoma cells ENZA-induced cell death can be inhibited by zVADfmk (Querfeld et al. 2006) . ENZA-dependent cleavage of caspases 3 and 8 has also been reported in multiple myeloma cells (Podar et al. 2007) . In contrast, in the multiple myeloma cell line MM1.S, cell death induced by ENZA at similar concentrations as in our experiments was not prevented by inhibition of caspases . Further, ENZA-induced apoptosis was associated with mitochondrial cytochrome c release in T98G cells (Fig. 2c) . In addition, expression of BCL-X L strongly prevented ENZA-induced cell death. These results suggest that ENZA induces cell death in glioma cells via the "intrinsic" cell death pathway (Igney & Krammer 2002 ) that is associated with the release of mitochondrial cytochrome c and can be inhibited by antiapoptotic members of the BCL-2 protein family.
It has been proposed that ENZA-induced cell death is a result of inhibition of the PI3K signaling pathway because treatment with ENZA was associated with reduced phosphorylation of Akt in several tumor cell lines (Moreau et al. 2007; Querfeld et al. 2006; Graff et al. 2005) . However, ENZA, though inducing cell death, did not reduce Akt phosphorylation in T98G glioma cells ( With regard to the literature, ENZA has also been reported to result in reduced phosphorylation of S6 protein in colon carcinoma cells (Graff et al. 2005) , in cutaneous lymphoma cells (Querfeld et al. 2006) , in Waldenstrom macroglobulinemia cells (Moreau et al. 2007 ) and in gastric cancer cells (Lee et al. 2008 (Fig. 5) , whereas we detected activation of caspases only after longer treatment periods (Fig. 2a) . Since ENZA inhibited phosphorylation of p70 S6 kinase in T98G cells without inhibiting phosphorylation of Akt ( Fig. 1) , it seems that the ENZAmediated decrease of phosphorylation of p70 S6 kinase is not a result of PI3K signaling inhibition. Therefore, the mechanisms by which ENZA inhibits phosphorylation of p70 S6 kinase remain elusive.
In line with previous observations that reduced phosphorylation of GSK-3β serves as a surrogate marker for ENZA activity (Graff et al. 2005) , we also detected dephosphorylation of GSK-3β in response to ENZA in glioma cells (Fig. 5) . ENZA resulted in reduced phosphorylation of GSK-3β in ENZA-resistant A172 cells under the indicated conditions. In addition, expression of BCL-X L strongly inhibited ENZAinduced cell death, but did not rescue the phosporylation of GSK-3β (Fig. 5b) .
Therefore, dephosporylation of GSK-3β and induction of cell death through ENZA are apparently separately regulated. It has been shown that GSK-3β can be phosphorylated by PKC (Goode et al. 1992) and Akt (Cross et al. 1995) . Yet, treatment with inhibitors of the PI3K signaling pathway did not reduce phosphorylation of GSK-3β in A172 glioma cells (Fig. 6a) , and expression of active Akt only marginally rescued ENZA-induced dephosphorylation of GSK-3β (Fig. 6b) .
Therefore, phosphorylation of GSK-3β seems to be mainly controlled by PKC in the examined cell lines whereas the influence of Akt signaling does not seem to be relevant.
How could the resistance of A172 cells towards ENZA be overcome? In A172 cells and in the glioblastoma-initiating cells, T 269 and T 323, Apo2L.0 induced cleavage of caspases 3, 8 and 9 which was enhanced by addition of ENZA, resulting in synergistic activity of ENZA and Apo2L.0 (Fig. 7 and data not shown) . In addition to the synergistic effects of ENZA and radiotherapy, this is a further combined regimen successfully evaluating sensitization towards or by ENZA, an also provides one potential mechanism to overcome resistance towards APO2.L in primary glioma cells (Rieger et al. 2007) . These data dissect the signaling cascade underlying the induction of apoptosis by the novel PKC-β-inhibitor ENZA and suggest activation of the "extrinsic" apoptosis pathway by Apo2L.0 as a measure to overcome resistance.
In conclusion, these results demonstrate that, in some glioma cells, ENZA induces caspase-dependent apoptosis that is likely to be independent from PI3K signaling. fragments.
Figure Legends
